PL3235824T3 - Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu - Google Patents

Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu

Info

Publication number
PL3235824T3
PL3235824T3 PL17169878T PL17169878T PL3235824T3 PL 3235824 T3 PL3235824 T3 PL 3235824T3 PL 17169878 T PL17169878 T PL 17169878T PL 17169878 T PL17169878 T PL 17169878T PL 3235824 T3 PL3235824 T3 PL 3235824T3
Authority
PL
Poland
Prior art keywords
alaninyl
gemcitabine
benzyloxy
phenyl
phosphate
Prior art date
Application number
PL17169878T
Other languages
English (en)
Inventor
Christopher Mcguigan
Fabrizio PERTUSATI
Original Assignee
University College Cardiff Consultants Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49622844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3235824(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1220666.0A external-priority patent/GB201220666D0/en
Priority claimed from GB201307314A external-priority patent/GB201307314D0/en
Application filed by University College Cardiff Consultants Limited filed Critical University College Cardiff Consultants Limited
Publication of PL3235824T3 publication Critical patent/PL3235824T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J27/00—Catalysts comprising the elements or compounds of halogens, sulfur, selenium, tellurium, phosphorus or nitrogen; Catalysts comprising carbon compounds
    • B01J27/06—Halogens; Compounds thereof
    • B01J27/128—Halogens; Compounds thereof with iron group metals or platinum group metals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y20/00—Nanooptics, e.g. quantum optics or photonic crystals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01S—DEVICES USING THE PROCESS OF LIGHT AMPLIFICATION BY STIMULATED EMISSION OF RADIATION [LASER] TO AMPLIFY OR GENERATE LIGHT; DEVICES USING STIMULATED EMISSION OF ELECTROMAGNETIC RADIATION IN WAVE RANGES OTHER THAN OPTICAL
    • H01S5/00—Semiconductor lasers
    • H01S5/30—Structure or shape of the active region; Materials used for the active region
    • H01S5/34—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
    • H01S5/343—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser
    • H01S5/34326—Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser, InP-based laser with a well layer based on InGa(Al)P, e.g. red laser

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Urology & Nephrology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17169878T 2012-11-16 2013-11-15 Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu PL3235824T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1220666.0A GB201220666D0 (en) 2012-11-16 2012-11-16 Process for preparing chemical compounds
GB201307314A GB201307314D0 (en) 2013-04-23 2013-04-23 Process for preparing chemical compounds
EP16195036.5A EP3150616B1 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
PCT/GB2013/053018 WO2014076490A1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs
EP17169878.0A EP3235824B1 (en) 2012-11-16 2013-11-15 Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
EP13792965.9A EP2920192B1 (en) 2012-11-16 2013-11-15 Process for preparing nucleoside prodrugs

Publications (1)

Publication Number Publication Date
PL3235824T3 true PL3235824T3 (pl) 2019-09-30

Family

ID=49622844

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16195036T PL3150616T3 (pl) 2012-11-16 2013-11-15 Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu
PL17169878T PL3235824T3 (pl) 2012-11-16 2013-11-15 Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL16195036T PL3150616T3 (pl) 2012-11-16 2013-11-15 Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu

Country Status (28)

Country Link
US (3) US10005810B2 (pl)
EP (3) EP3235824B1 (pl)
JP (5) JP2016506371A (pl)
KR (1) KR20150103669A (pl)
CN (2) CN104903339A (pl)
AU (1) AU2013346515B2 (pl)
CA (1) CA2891266C (pl)
CL (1) CL2015001307A1 (pl)
CY (2) CY1119161T1 (pl)
DK (2) DK3235824T3 (pl)
EA (1) EA028871B1 (pl)
ES (3) ES2618732T3 (pl)
HK (1) HK1210784A1 (pl)
HR (2) HRP20170791T1 (pl)
HU (2) HUE033335T2 (pl)
IL (1) IL238792A (pl)
IN (1) IN2015DN04090A (pl)
LT (2) LT3150616T (pl)
MX (1) MX2015006195A (pl)
MY (1) MY176133A (pl)
NZ (1) NZ708177A (pl)
PH (1) PH12015501090A1 (pl)
PL (2) PL3150616T3 (pl)
PT (2) PT3150616T (pl)
RS (2) RS58849B1 (pl)
SG (3) SG10201510324YA (pl)
SI (2) SI3150616T1 (pl)
WO (1) WO2014076490A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
JP2017504572A (ja) * 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CN105153257B (zh) * 2014-06-12 2019-03-05 正大天晴药业集团股份有限公司 索非布韦的制备方法
SI3119794T1 (en) 2014-06-25 2018-02-28 NuCana plc FORMULATION, COMPOSITION OF GEMCITABIN PREPARED
CN106459129B (zh) * 2014-06-25 2020-03-31 努卡那有限公司 吉西他滨前药
CN105254694B (zh) * 2014-07-14 2018-11-27 正大天晴药业集团股份有限公司 氘代核苷衍生物
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
MX2017001459A (es) * 2014-07-31 2017-05-23 Sandoz Ag Sintesis de fosforamidatos.
US9675632B2 (en) 2014-08-26 2017-06-13 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN105461773B (zh) * 2014-09-30 2020-12-01 江苏豪森药业集团有限公司 索非布韦的制备方法及其中间体
CN105461774B (zh) * 2014-09-30 2020-11-24 江苏豪森药业集团有限公司 索非布韦的制备方法
GB201417644D0 (en) * 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
KR20220025914A (ko) 2015-03-06 2022-03-03 아테아 파마슈티컬즈, 인크. HCV 치료를 위한 β-D-2'-데옥시-2'-α-플루오로-2'-β-C-치환된-2-변형된-N6-치환된 퓨린 뉴클레오티드
EP3274356A1 (en) 2015-03-26 2018-01-31 Química Sintética, S.A. Nucleoside phosphoramidates useful for the treatment of viral infections and preparation thereof
CN106397515B (zh) * 2015-07-28 2021-05-11 广东东阳光药业有限公司 一种改良的索菲布韦制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
WO2017090264A1 (ja) * 2015-11-27 2017-06-01 大原薬品工業株式会社 ５－アザシチジン又は其の２'－デオキシ体の５'位ジベンジル燐酸エステル
PT3386998T (pt) * 2015-12-11 2021-11-30 NuCana plc Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311
GB201522771D0 (en) * 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201609602D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
LU100724B1 (en) 2016-07-14 2018-07-31 Atea Pharmaceuticals Inc Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
US10239910B2 (en) * 2016-07-20 2019-03-26 Optimus Drugs (P) Limited Process for the preparation of sofosbuvir
WO2018019188A1 (zh) * 2016-07-23 2018-02-01 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的多晶型及其制备方法
KR20190043602A (ko) 2016-09-07 2019-04-26 아테아 파마슈티컬즈, 인크. Rna 바이러스 치료를 위한 2'-치환된-n6-치환된 퓨린 뉴클레오티드
US10266558B2 (en) * 2016-10-07 2019-04-23 Alexandre Vasilievich Ivachtchenko Macroheterocyclic nucleoside derivatives and their analogues, production and use thereof
AU2017378959B2 (en) * 2016-12-23 2021-09-09 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Nucleoside phosphate compound and preparation method and use thereof
MY201105A (en) 2017-02-01 2024-02-06 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
EP3773753A4 (en) 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS
CN111989335B (zh) 2018-06-12 2023-06-13 四川科伦博泰生物医药股份有限公司 膦酰胺酯化合物及其盐和相关晶体形式、制备方法和用途
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
RU2740058C1 (ru) * 2020-06-26 2020-12-31 Общество С Ограниченной Ответственностью "Технология Лекарств" Способ получения софосбувира и фосфорамидаты
CN112409431B (zh) * 2020-12-07 2023-04-21 武汉伯瑞恒医药科技有限公司 阿糖胞苷结构类似物及其制备方法和用途
CN113549076B (zh) * 2021-07-23 2022-12-06 中国药科大学 一种多取代嘌呤类化合物及其制备方法和应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
CA2317505C (en) 1998-01-23 2011-01-04 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
NZ534811A (en) 2002-02-14 2007-07-27 Pharmasset Inc Modified fluorinated nucleoside analogues
US7265096B2 (en) 2002-11-04 2007-09-04 Xenoport, Inc. Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
CA2618335C (en) * 2005-08-15 2015-03-31 F.Hoffmann-La Roche Ag Antiviral phosphoramidates of 4'-substituted pronucleotides
GB0623493D0 (en) * 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
PA8852101A1 (es) * 2008-12-08 2010-07-27 Medivir Ab Nucleótidos uracil ciclopropílicos
PE20120013A1 (es) * 2009-01-09 2012-02-02 Univ Cardiff Fosforamidato derivados de guanosina compuestos nucleosidos para tratamiento de infecciones virales
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
SI2609923T1 (sl) * 2010-03-31 2017-10-30 Gilead Pharmasset Llc Postopek za kristalizacijo (s)-izopropil 2-(((s)-(perfluorofenoksi) (fenoksi)fosforil)amino)propanoata
US9090642B2 (en) * 2010-07-19 2015-07-28 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
CN105061534A (zh) * 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
WO2012088155A1 (en) * 2010-12-22 2012-06-28 Alios Biopharma, Inc. Cyclic nucleotide analogs
HUE029022T2 (en) * 2011-03-01 2017-02-28 Nucana Biomed Ltd Phosphoramidate derivatives of 5-fluoro-2'-deoxyuridine for use in the treatment of cancer
KR20190060879A (ko) * 2011-03-02 2019-06-03 제롬 쉔타그 단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
MX2014004415A (es) * 2011-10-14 2015-06-05 Stc Unm Bicapas lipidicas soportadas por nanoparticulas porosas (protecelulas) para suministro dirigido, incluido el suministro transdermico de carga, y los metodos relacionados.
US10005810B2 (en) * 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
CA2913206C (en) * 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
JP6762873B2 (ja) 2013-09-11 2020-09-30 エモリー・ユニバーシテイ ヌクレオチドおよびヌクレオシド組成物ならびにこれらに関連する使用
KR102314960B1 (ko) * 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
KR20160079846A (ko) * 2013-11-27 2016-07-06 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 피페리딘 및 피페라진 유도체, 및 바이러스 감염 및 암 치료에서의 그의 용도
JP2017504572A (ja) 2013-11-27 2017-02-09 アイデニクス・ファーマシューティカルズ・エルエルシー 肝臓癌治療のためのヌクレオチド類
CN106459129B (zh) 2014-06-25 2020-03-31 努卡那有限公司 吉西他滨前药
SI3119794T1 (en) 2014-06-25 2018-02-28 NuCana plc FORMULATION, COMPOSITION OF GEMCITABIN PREPARED
EP3172218B1 (en) 2014-07-22 2020-10-21 NuCana plc Process for the preparation of gemcitabine-[phenyl(benzoxy-l-alaninyl)] phosphate
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
KR20180021697A (ko) 2015-05-14 2018-03-05 뉴카나 피엘씨 암 치료
US10660912B2 (en) 2015-10-05 2020-05-26 NuCana plc Combination therapy for cancer
PT3386998T (pt) 2015-12-11 2021-11-30 NuCana plc Síntese diastereosseletiva de derivados fosfato e do pró-fármaco gemcitabina nuc-10311
KR102566461B1 (ko) 2015-12-23 2023-08-14 뉴카나 피엘씨 조합 요법
HUE050290T2 (hu) 2015-12-23 2020-11-30 NuCana plc Kombinált terápia
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201713914D0 (en) 2017-08-30 2017-10-11 Nucana Biomed Ltd Combination therapy

Also Published As

Publication number Publication date
WO2014076490A1 (en) 2014-05-22
ES2725491T3 (es) 2019-09-24
IL238792A0 (en) 2015-06-30
US20220033433A1 (en) 2022-02-03
CY1119161T1 (el) 2018-02-14
ES2618732T3 (es) 2017-06-22
CN104903339A (zh) 2015-09-09
JP2021020919A (ja) 2021-02-18
AU2013346515B2 (en) 2017-05-25
EP3235824B1 (en) 2019-03-27
US20180273575A1 (en) 2018-09-27
LT3150616T (lt) 2017-07-25
PT3235824T (pt) 2019-05-30
HUE044605T2 (hu) 2019-11-28
US10005810B2 (en) 2018-06-26
CN111592577A (zh) 2020-08-28
MX2015006195A (es) 2015-12-08
NZ708177A (en) 2017-08-25
JP2018009000A (ja) 2018-01-18
DK3150616T3 (en) 2017-06-06
SI3235824T1 (sl) 2019-08-30
HUE033335T2 (en) 2017-11-28
MY176133A (en) 2020-07-24
CY1121663T1 (el) 2020-07-31
EP2920192A1 (en) 2015-09-23
RS58849B1 (sr) 2019-07-31
SG10201510324YA (en) 2016-01-28
RS56038B1 (sr) 2017-09-29
PH12015501090B1 (en) 2015-07-27
CA2891266A1 (en) 2014-05-22
CL2015001307A1 (es) 2015-12-11
SG10201510322UA (en) 2016-01-28
JP2019196360A (ja) 2019-11-14
HK1210784A1 (en) 2016-05-06
EP3150616A1 (en) 2017-04-05
PH12015501090A1 (en) 2015-07-27
ES2627195T3 (es) 2017-07-27
US11040997B2 (en) 2021-06-22
EP3235824A1 (en) 2017-10-25
CA2891266C (en) 2020-12-08
AU2013346515A1 (en) 2015-06-04
JP2016506371A (ja) 2016-03-03
SG11201503750YA (en) 2015-06-29
DK3235824T3 (da) 2019-05-20
PL3150616T3 (pl) 2017-09-29
LT3235824T (lt) 2019-07-10
IN2015DN04090A (pl) 2015-10-09
JP2023052536A (ja) 2023-04-11
BR112015011155A2 (pt) 2017-07-11
HRP20190831T1 (hr) 2019-08-23
EA028871B1 (ru) 2018-01-31
IL238792A (en) 2017-09-28
HRP20170791T1 (hr) 2017-08-25
EP2920192B1 (en) 2017-02-22
US20150291650A1 (en) 2015-10-15
SI3150616T1 (sl) 2017-08-31
EP3150616B1 (en) 2017-05-10
PT3150616T (pt) 2017-06-09
KR20150103669A (ko) 2015-09-11
EA201590955A1 (ru) 2015-08-31

Similar Documents

Publication Publication Date Title
PL3235824T3 (pl) Mieszanina Rp/Sp gemcytabino-[fenylo-(benzyloksy-l-alaninylo)]-fosforynu
IL276761A (en) Methods of inducing coma
SG11201405573WA (en) Production of graphene
HK1211563A1 (en) Synthesis of micro-sized interconnected si-c composites si-c
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (en) OLIGOMERATZUSAMMENSETZUNG
HUE038638T2 (hu) Inhalátor
IL236312A0 (en) Preparation of 18f-flucyclobin
EP2881113A4 (en) NEW APPLICATION OF POGOSTONE
HK1203355A1 (en) Uses of 4-desferrithiocin analogs 4-
ZA201209245B (en) Rubber mixture
IL219244A0 (en) Splitting of user-lists
EP2892529A4 (en) USES OF (-) - PERHEXILINE
GB201312378D0 (en) Structure of shoe
GB2503216B (en) Continuity of content
EP2804612A4 (en) THERAPEUTIC USES OF TETRACHLORODECAOXYGEN (TCDO)
PT2846806T (pt) Tratamento para depressão respiratória
GB201207907D0 (en) Treatment of depression
GB201209895D0 (en) Use of a composition
AU2012905067A0 (en) IMPROVED INHIBITORS OF Grb7
TWM433525U (en) Structure of calorifier
TWM438663U (en) Mouse capable of adjusting sound volume
ZA201104679B (en) Suppression of cancers
GB201222952D0 (en) Treatent of cancer